• If you are wondering whether Iovance Biotherapeutics at US$3.62 offers value or just more volatility, starting with a clear look at price and fundamentals can help you frame the opportunity.
• The stock is down 6.9% over the last 7 days, up 26.1% over 30 days, up 43.7% year to date, but still shows a 4.0% return over 1 year, a 41.7% decline over 3 years and an 87.8% decline over 5 years, which points to a history of sharp swings in sentiment and risk perception.
• Recent coverage has focused on Iovance Biotherapeutics as a clinical stage biotech, where progress on its cell therapy programs and regulatory milestones often sets the tone for market expectations. News around trial updates, approvals or capital raising plans tends to feed directly into these price moves, as investors reassess both risk and potential reward.
• On Simply Wall St's valuation checks, the company scores 4 out of 6, which points to some indicators suggesting undervaluation, and the next sections will compare different valuation approaches before finishing with a broader way to think about what that score really means for you.

Approach 1: Iovance Biotherapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock could be worth by projecting future cash flows and then discounting them back to today’s value using a required return. For Iovance Biotherapeutics, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in $.

The latest twelve month free cash flow is a loss of about $343.7 million, so the starting point is clearly negative. Analysts and model estimates then project a path toward positive free cash flow, with a forecast of $313 million by 2030. The ten year projection set ranges from losses in 2026 and 2027 to positive free cash flows above $500 million per year by 2035, all discounted back to reflect risk and the time value of money.

Pulling these projections together, the DCF model points to an estimated intrinsic value of about $23.55 per share. Against the current share price of US$3.62, this implies an 84.6% discount, which suggests the stock screens as heavily undervalued on this specific cash flow model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Iovance Biotherapeutics is undervalued by 84.6%. Track this in your watchlist or portfolio, or discover 58 more high quality undervalued stocks.

Approach 2: Iovance Biotherapeutics Price vs Sales

For companies that are not yet profitable, earnings based ratios like P/E are less useful, so investors often focus on revenue based metrics such as the Price to Sales, or P/S, ratio to get a simple sense of how much the market is paying for each dollar of sales.

What counts as a “normal” or “fair” P/S ratio can vary a lot, since higher growth expectations or lower perceived risk can support higher multiples, while slower growth or higher risk usually points to lower multiples being more reasonable.

Iovance Biotherapeutics currently trades on a P/S ratio of 5.66x. That sits below the Biotechs industry average P/S of 10.63x and also below the peer group average of 10.38x, which suggests the stock is priced at a lower level of sales compared with many similar names.

Simply Wall St’s “Fair Ratio” is a proprietary estimate of what P/S might be appropriate for this specific company, at 4.16x, based on factors such as its earnings profile, industry, profit margins, market value and risk characteristics.

Because the Fair Ratio directly incorporates these company specific drivers, it can be more informative than a simple comparison with broad industry or peer averages that may not share the same growth or risk mix. Set against this 4.16x Fair Ratio, the current 5.66x P/S suggests the shares trade at a higher multiple of sales than the model implies.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Iovance Biotherapeutics Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so meet Narratives, a simple tool on Simply Wall St’s Community page that lets you connect your view of Iovance Biotherapeutics to a set of forecast numbers and a Fair Value, then compare that Fair Value to the current price to assess whether the stock appears attractive based on your own assumptions.

A Narrative is your story about the company expressed in numbers. You link beliefs about future revenue, earnings and margins to a valuation. For Iovance Biotherapeutics, that can range from a very cautious view that aligns with a US$1.00 Fair Value to a more optimistic stance closer to US$20.00, with a mid range view around US$9.10 in between.

Because Narratives on the platform are refreshed when new news, earnings or guidance are added, you can see how different investors update their stories over time and decide which version of Iovance Biotherapeutics, whether cautious, optimistic or somewhere in the middle, feels closest to your own judgement.

Do you think there's more to the story for Iovance Biotherapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.